Showing results (21-30 of 35) with videos related to

Sort By:
Pageof 4
Blood Advances|December 12, 2018
p53 regulates CD46 expression and measles virus infection in myeloma cellsAnne Lok, Geraldine Descamps, Benoit Tessoulin, et al.
Scientific Reports|September 22, 2020
Antithymocyte globulin administration in patients with profound lymphopenia receiving a PBSC purine analog/busulfan-based conditioning regimen allograftMaxime Jullien, Thierry Guillaume, Pierre Peterlin, et al.
Blood|December 14, 2023
A p53 score derived from TP53 CRISPR/Cas9 HMCLs predicts survival and reveals a major role of BAX in the response to BH3 mimeticsRomane Durand, Géraldine Descamps, Céline Bellanger, et al.
Hematological Oncology|May 31, 2020
Whole genome copy number analysis in search of new prognostic biomarkers in first line treatment of mantle cell lymphoma. A study by the LYSA groupYannick Le Bris, Florence Magrangeas, Anne Moreau, et al.
American Journal of Hematology|January 2, 2024
Phase I study of zoledronic acid combined with escalated doses of interleukine-2 for early in vivo generation of Vγ9Vδ2 T-cells after haploidentical stem cell transplant with posttransplant cyclophosphamideMaxime Jullien, Thierry Guillaume, Amandine Le Bourgeois, et al.
International Journal of Laboratory Hematology|September 14, 2024
Deep Learning-Based Blood Abnormalities Detection as a Tool for VEXAS Syndrome ScreeningCédric De Almeida Braga, Maxence Bauvais, Pierre Sujobert, et al.
Cancer Medicine|December 28, 2020
A new cytokine-based dynamic stratification during induction is highly predictive of survivals in acute myeloid leukemiaPierre Peterlin, Joelle Gaschet, Thierry Guillaume, et al.
Cytokine|April 30, 2019
FLT3 ligand plasma levels have no impact on outcomes after allotransplant in acute leukemiaPierre Peterlin, Joelle Gaschet, Thierry Guillaume, et al.
The Lancet. Haematology|May 28, 2023
CPX-351 in higher risk myelodysplastic syndrome and chronic myelomonocytic leukaemia: a multicentre, single-arm, phase 2 studyPierre Peterlin, Yannick Le Bris, Pascal Turlure, et al.
Acta Oncologica (Stockholm, Sweden)|October 28, 2020
Grade 2 acute GVHD is a factor of good prognosis in patients receiving peripheral blood stem cells haplo-transplant with post-transplant cyclophosphamidePatrice Chevallier, Ana Berceanu, Pierre Peterlin, et al.
Pageof 4